Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
BHVN Stock Chart & Stats
$11.39
-$0.59(-1.49%)
At close: 4:00 PM EST
$11.39
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $40.82
Previous CloseN/A
Volume146.24K
Average Volume (3M)2.69M
Market Cap
$1.68B
Enterprise Value$1.35B
Total Cash (Recent Filing)$260.22M
Total Debt (Recent Filing)$314.18M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 19, 2026EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding145,188,490
10 Day Avg. Volume2,230,108
30 Day Avg. Volume2,687,457
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.22K
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$17.33Price Target Upside52.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.11
Revenue Forecast (FY)$2.26M
Bulls Say, Bears Say
Bulls Say
Early Biomarker EvidenceEarly biomarker changes reported in the MoDE and TRAP programs are unlikely to be spontaneous and support biological activity that could reduce clinical development risk for those assets.
Lead Asset PotentialBHV-1400 targets the abnormal IgA protein driving IgA nephropathy and could act as a best-in-class degrader that permits chronic treatment while avoiding broad immunosuppression.
Strategic Portfolio FocusManagement is concentrating resources on immunology, obesity, and epilepsy and implementing cost optimization to preserve cash and advance higher‑value late stage programs.
Bears Say
Clinical Program UncertaintyBHV-7000 failed to meet its primary endpoint in the depression study and lingering concerns about brain exposure for the Kv7 mechanism create uncertainty about future central nervous system outcomes.
Financial Runway PressureAvailable cash is limited relative to historical spending, prompting aggressive R&D reductions and prioritization that shrink the company's development optionality.
Regulatory SetbackFDA issued a complete response letter for Vyglxia and flagged the use of real‑world data as a comparator, raising material questions about the path to approval.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $40.82 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.68B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Mar 19, 2026 which is in 26 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Nov 10, 2025. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.901 by $0.261.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -1.19.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 145,188,490 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.901. Following the earnings report the stock price went down -5.69%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.33 (52.15% Upside)
$17.33 (52.15% Upside)
Blogger Sentiment
Neutral
BHVN Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.70%
12-Months-Change
Fundamentals
Return on Equity
-522.08%
Trailing 12-Months
Asset Growth
-19.86%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
BHVN Stock 12 Month Forecast
Average Price Target
$17.33
▲(52.15% Upside)
Technical Analysis
Ownership Overview
11.15% Insiders
10.68% Mutual Funds
6.84% Other Institutional Investors
62.22% Public Companies and
Individual Investors